Alcon (ALC)

Executive Summary

Alcon is a global leader in eye care, with a 75-year heritage of developing innovative vision solutions. The company operates through two complementary segments: Surgical and Vision Care, serving patients in over 140 countries. Alcon's surgical business offers advanced intraocular lenses (IOLs), cataract and vitreoretinal equipment, while its vision care segment provides contact lenses, lens care products, and ocular health solutions. The company benefits from an aging population, increasing cataract surgeries, and rising contact lens adoption. Alcon's strong R&D pipeline and strategic acquisitions have solidified its position as the second-largest eye care company globally. With a valuation of ~$38 billion and robust cash flow, Alcon is well-positioned to capitalize on growth trends in emerging markets and premium technology segments.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of PanOptix Trifocal IOL next-generation platform80% success
• Q4 2026Launch of Precision1 contact lens in Asia-Pacific markets90% success
• TBDPotential acquisition of a digital health start-up for glaucoma monitoring60% success